KR20080017382A - Ｇａｂａ ｂ 매개된 신경계 장애 치료용 피리미딘 유도체 - Google Patents
Ｇａｂａ ｂ 매개된 신경계 장애 치료용 피리미딘 유도체 Download PDFInfo
- Publication number
- KR20080017382A KR20080017382A KR1020077029918A KR20077029918A KR20080017382A KR 20080017382 A KR20080017382 A KR 20080017382A KR 1020077029918 A KR1020077029918 A KR 1020077029918A KR 20077029918 A KR20077029918 A KR 20077029918A KR 20080017382 A KR20080017382 A KR 20080017382A
- Authority
- KR
- South Korea
- Prior art keywords
- unsubstituted
- compound
- formula
- substituted
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *c1c(*)nc(*)nc1* Chemical compound *c1c(*)nc(*)nc1* 0.000 description 3
- QZGPFHNBAOUYHF-UHFFFAOYSA-N Cc(cc1)ccc1-c1c(NC2CCCC2)nc(C)nc1Cl Chemical compound Cc(cc1)ccc1-c1c(NC2CCCC2)nc(C)nc1Cl QZGPFHNBAOUYHF-UHFFFAOYSA-N 0.000 description 2
- LYYCKUQHNXQXBZ-UHFFFAOYSA-N CCCCc1cc(-c2c(NC3CCCC3)nc(C)nc2Cl)ccc1 Chemical compound CCCCc1cc(-c2c(NC3CCCC3)nc(C)nc2Cl)ccc1 LYYCKUQHNXQXBZ-UHFFFAOYSA-N 0.000 description 1
- SAFXUQXGJZLMGA-UHFFFAOYSA-N CCCCc1cccc(-c2cnc(C)nc2NC2CCCC2)c1 Chemical compound CCCCc1cccc(-c2cnc(C)nc2NC2CCCC2)c1 SAFXUQXGJZLMGA-UHFFFAOYSA-N 0.000 description 1
- NARAHGVYHXOKRA-UHFFFAOYSA-N Cc(cc1)ccc1-c1c(NC2CCCC2)nc(C)nc1NC1CCCC1 Chemical compound Cc(cc1)ccc1-c1c(NC2CCCC2)nc(C)nc1NC1CCCC1 NARAHGVYHXOKRA-UHFFFAOYSA-N 0.000 description 1
- NEDJTEXNSTUKHW-UHFFFAOYSA-N Cc(nc1)ncc1Br Chemical compound Cc(nc1)ncc1Br NEDJTEXNSTUKHW-UHFFFAOYSA-N 0.000 description 1
- BSLIRQAPDNSSAT-UHFFFAOYSA-N Cc(nc1NC2CCCC2)nc(Cl)c1I Chemical compound Cc(nc1NC2CCCC2)nc(Cl)c1I BSLIRQAPDNSSAT-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N Cc1ccc(B(O)O)cc1 Chemical compound Cc1ccc(B(O)O)cc1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- LSDHENHBPCJSQN-UHFFFAOYSA-N Cc1nc(NC2CCCC2)c(-c(cc2)cc(OC)c2OC)c(Cl)n1 Chemical compound Cc1nc(NC2CCCC2)c(-c(cc2)cc(OC)c2OC)c(Cl)n1 LSDHENHBPCJSQN-UHFFFAOYSA-N 0.000 description 1
- VAISFLLBEDITFU-UHFFFAOYSA-N Cc1nc(NC2CCCC2)c(-c(cc2)ccc2OC)c(Cl)n1 Chemical compound Cc1nc(NC2CCCC2)c(-c(cc2)ccc2OC)c(Cl)n1 VAISFLLBEDITFU-UHFFFAOYSA-N 0.000 description 1
- NTEWQFRZQLOYMT-UHFFFAOYSA-N Cc1ncc(-c(cc2OC)ccc2OC)c(NC2CCCC2)n1 Chemical compound Cc1ncc(-c(cc2OC)ccc2OC)c(NC2CCCC2)n1 NTEWQFRZQLOYMT-UHFFFAOYSA-N 0.000 description 1
- GIFDWXWNFKZVEI-UHFFFAOYSA-N FC(c(nc1)ncc1Br)(F)F Chemical compound FC(c(nc1)ncc1Br)(F)F GIFDWXWNFKZVEI-UHFFFAOYSA-N 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N NC1CCCC1 Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- XWEQTFIMBKOOJZ-UHFFFAOYSA-N O=Nc(c(Cl)nc(C(F)(F)F)n1)c1Cl Chemical compound O=Nc(c(Cl)nc(C(F)(F)F)n1)c1Cl XWEQTFIMBKOOJZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0512844.2 | 2005-06-23 | ||
| GBGB0512844.2A GB0512844D0 (en) | 2005-06-23 | 2005-06-23 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080017382A true KR20080017382A (ko) | 2008-02-26 |
Family
ID=34856051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077029918A Withdrawn KR20080017382A (ko) | 2005-06-23 | 2006-06-23 | Ｇａｂａ ｂ 매개된 신경계 장애 치료용 피리미딘 유도체 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100179127A1 (https=) |
| EP (1) | EP1896428A1 (https=) |
| JP (1) | JP2008546731A (https=) |
| KR (1) | KR20080017382A (https=) |
| CN (1) | CN101193868A (https=) |
| AU (1) | AU2006261122A1 (https=) |
| BR (1) | BRPI0613394A2 (https=) |
| CA (1) | CA2610742A1 (https=) |
| GB (1) | GB0512844D0 (https=) |
| MX (1) | MX2007016395A (https=) |
| RU (1) | RU2008101525A (https=) |
| WO (1) | WO2006136442A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009143183A1 (en) | 2008-05-19 | 2009-11-26 | University Of Tennessee Research Foundation, The | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| US8389534B2 (en) | 2008-05-19 | 2013-03-05 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| JP5619743B2 (ja) * | 2008-08-20 | 2014-11-05 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用 |
| TW201020245A (en) * | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| TWI409265B (zh) * | 2008-08-20 | 2013-09-21 | Merck Sharp & Dohme | 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途 |
| US8470834B2 (en) | 2008-08-20 | 2013-06-25 | Merck Sharp & Dohme Corp. | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| WO2010045377A2 (en) * | 2008-10-14 | 2010-04-22 | University Of Tennessee Research Foundation, The | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| KR20180084153A (ko) | 2011-06-10 | 2018-07-24 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| WO2013066729A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9637505B2 (en) | 2013-03-15 | 2017-05-02 | Dow Agrosciences Llc | 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides |
| CN110583663A (zh) | 2013-03-15 | 2019-12-20 | 美国陶氏益农公司 | 式(i)化合物及其作为除草剂的用途 |
| EP2970186B1 (en) * | 2013-03-15 | 2020-06-10 | Dow AgroSciences LLC | 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic) pyrimidine-4-carboxylates and their use as herbicides |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| TW201623257A (zh) | 2014-05-09 | 2016-07-01 | 奧利安公司 | 藥理活性之喹唑啉二酮衍生物 |
| TWI689251B (zh) | 2014-09-15 | 2020-04-01 | 美商陶氏農業科學公司 | 源自於施用吡啶羧酸除草劑與合成生長素除草劑及/或生長素轉運抑制劑的協同性雜草控制 |
| TWI685302B (zh) | 2014-09-15 | 2020-02-21 | 美商陶氏農業科學公司 | 包含吡啶羧酸除草劑之安全的除草組成物 |
| US10455836B2 (en) | 2014-09-15 | 2019-10-29 | Dow Agrosciences Llc | Synergistic weed control from applications of pyridine carboxylic acid herbicides and photosystem II inhibitors |
| TWI694770B (zh) | 2014-09-15 | 2020-06-01 | 美商陶氏農業科學公司 | 包含吡啶羧酸除草劑之安全的除草組成物（二） |
| TWI689252B (zh) | 2014-09-15 | 2020-04-01 | 美商陶氏農業科學公司 | 源自於施用吡啶羧酸除草劑與乙醯乳酸合成酶（ａｌｓ）抑制劑的協同性雜草控制 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| KR102780243B1 (ko) * | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI907472B (zh) | 2020-08-05 | 2025-12-11 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023172475A2 (en) * | 2022-03-11 | 2023-09-14 | Merck Sharp & Dohme Llc | Non-aromatic cyclic-pyrimidine analogs as glucosylceramide synthase inhibitors |
| CN116496223A (zh) * | 2023-04-26 | 2023-07-28 | 福建凯昕药业有限公司 | 5-溴-4-甲基-2-三氟甲基嘧啶的一种制备方法 |
| GB202414192D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414193D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414197D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414200D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414199D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel Compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH558137A (de) * | 1971-05-17 | 1975-01-31 | Ciba Geigy Ag | Mittel zur beeinflussung des pflanzenwachstums. |
| CH560197A5 (en) * | 1971-05-17 | 1975-03-27 | Ciba Geigy Ag | 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides |
| CH574206A5 (https=) * | 1972-11-16 | 1976-04-15 | Ciba Geigy Ag | |
| DE2341925A1 (de) * | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| CH595061A5 (https=) * | 1974-05-10 | 1978-01-31 | Ciba Geigy Ag | |
| CH617833A5 (https=) * | 1975-07-07 | 1980-06-30 | Ciba Geigy Ag | |
| SE9904129D0 (sv) * | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
| ATE303367T1 (de) * | 2000-06-13 | 2005-09-15 | 5 phenyl substituierte 2-(cyanoamino)-pyrimidine als fungizide | |
| SE0004099D0 (sv) * | 2000-11-09 | 2000-11-09 | Astrazeneca Ab | Novel compounds |
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| EP1590341B1 (en) * | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| US20090036448A1 (en) * | 2004-03-30 | 2009-02-05 | Taisho Pharmecutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
-
2005
- 2005-06-23 GB GBGB0512844.2A patent/GB0512844D0/en not_active Ceased
-
2006
- 2006-06-23 CA CA002610742A patent/CA2610742A1/en not_active Abandoned
- 2006-06-23 AU AU2006261122A patent/AU2006261122A1/en not_active Abandoned
- 2006-06-23 EP EP06762168A patent/EP1896428A1/en not_active Withdrawn
- 2006-06-23 KR KR1020077029918A patent/KR20080017382A/ko not_active Withdrawn
- 2006-06-23 JP JP2008517430A patent/JP2008546731A/ja active Pending
- 2006-06-23 BR BRPI0613394-0A patent/BRPI0613394A2/pt not_active IP Right Cessation
- 2006-06-23 WO PCT/EP2006/006083 patent/WO2006136442A1/en not_active Ceased
- 2006-06-23 RU RU2008101525/04A patent/RU2008101525A/ru not_active Application Discontinuation
- 2006-06-23 US US11/993,630 patent/US20100179127A1/en not_active Abandoned
- 2006-06-23 CN CNA2006800207941A patent/CN101193868A/zh active Pending
- 2006-06-23 MX MX2007016395A patent/MX2007016395A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006136442A1 (en) | 2006-12-28 |
| MX2007016395A (es) | 2008-03-07 |
| AU2006261122A1 (en) | 2006-12-28 |
| CA2610742A1 (en) | 2006-12-28 |
| JP2008546731A (ja) | 2008-12-25 |
| US20100179127A1 (en) | 2010-07-15 |
| CN101193868A (zh) | 2008-06-04 |
| GB0512844D0 (en) | 2005-08-03 |
| BRPI0613394A2 (pt) | 2011-01-11 |
| EP1896428A1 (en) | 2008-03-12 |
| RU2008101525A (ru) | 2009-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080017382A (ko) | Ｇａｂａ ｂ 매개된 신경계 장애 치료용 피리미딘 유도체 | |
| CA2762680C (en) | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics | |
| US20090018156A1 (en) | Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors | |
| KR102176667B1 (ko) | 항섬유성 피리디논 | |
| US20100113445A1 (en) | Chemical Compounds | |
| US20200131184A1 (en) | [1,2,4]triazolo[1,5-c]pyrimidine derivative as a2a receptor inhibitor | |
| CA2736281C (en) | Tri-substituted pyrimidine compounds and their use as pde10 inhibitors | |
| US20120309739A1 (en) | Akt / pkb inhibitors | |
| KR102495840B1 (ko) | PI3K 억제제로 사용되는 피리디노[1,2-a]피리미돈 유사체 | |
| JP2009532429A (ja) | 新規ビアリールアミン類 | |
| JP2007504243A (ja) | ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物 | |
| KR20240089791A (ko) | 메티오닌 아데노실트랜스퍼라제 2a (mat2a) 억제제 및 그의 용도 | |
| US20240254117A1 (en) | Pyrimido-heterocyclic compounds, and preparation method therefor and use thereof | |
| US7329678B2 (en) | Chemical compounds | |
| KR20200055126A (ko) | Ａ2ａ수용체 억제제로서의 축합 고리 유도체 | |
| WO2025218831A2 (zh) | 具有ptpn2/ptpn1抑制活性的噻二唑烷酮衍生物及其制备方法和应用 | |
| JPH05255327A (ja) | 複素環式誘導体 | |
| KR20090127272A (ko) | ｍＧｌｕＲ 리간드로서의 융합 피리미디논 화합물 | |
| KR102351270B1 (ko) | Akt 억제제인 디히드로피라졸로아제핀계 화합물 | |
| CN117126176A (zh) | 一种噻吩并嘧啶类化合物及其作为多巴胺d2受体别构拮抗剂的应用 | |
| KR20240006653A (ko) | Camkk2 억제제로서의 헤테로시클릭 유도체 | |
| WO2004076414A2 (en) | Novel compounds | |
| CN111808080B (zh) | 取代的吡啶或嘧啶化合物、其制备方法及其在医药上的应用 | |
| WO2024127363A1 (en) | Tyk2 pseudokinase ligands and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20071221 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |